1
|
Cataldo M, Granata G, Caraffa E, Adamoli L, Borromeo R, Fossati S, Franceschini E, Giacobbe D, Giacometti E, Lagi F, Lombardi A, Oliva A, Pandolfo A, Trapani F, Petrosillo N. Recurrence of Clostridioides difficile infection: A multicenter study on incidence and risk factors. Int J Infect Dis 2020. [DOI: 10.1016/j.ijid.2020.09.718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
2
|
Abstract
Objective: To report a case of erlotinib-induced breast cancer regression. Case Summary: A 38-year-old woman developed bilateral locoregional malignant cutaneous lymphangitis following a right subcutaneous mastectomy and 3 months of adjuvant chemotherapy. After several systemic chemotherapy regimens, the lymphangitis worsened rapidly, with progressive skin ulceration. Morphine and dexamethasone were given, with suboptimal pain control. A chemotherapy regimen of gemcitabine and vinorelbine was started. After 2 full-dose administrations, while lymphangitis continued to worsen, erlotinib 150 mg/day was added to the regimen. After 10 weeks of treatment, pain subsided and analgesics were discontinued. Physical examination revealed a partial regression of malignant cutaneous lymphangitis and pulmonary metastases, with resolution of ulceration. Discussion: There has been increased interest in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in the treatment of breast cancer. Gefitinib has shown a low level of efficacy, while preliminary clinical data on erlotinib were not conclusive and suggested lack of clinical activity. Molecular analysis of the tumor in our patient revealed a profile predictive of response to EGFR selective inhibitors in some patients with lung cancer. Conclusions: The addition of erlotinib to our patient's chemotherapy regimen resulted in antitumor activity in breast cancer in which an activated EGFR pathway was demonstrated. This finding is consistent with available preclinical and clinical data on EGFR tyrosine kinase inhibitors across tumor types and supports the efforts to optimize EGFR selective inhibitors in treating breast cancer and other malignancies.
Collapse
Affiliation(s)
- Chiara Catania
- Medical Care Unit, Department of Medicine, European Institute of Oncology, Milan, Italy.
| | | | | | | | | | | | | |
Collapse
|
3
|
Aurilio G, Sandri MT, Pruneri G, Zorzino L, Botteri E, Munzone E, Adamoli L, Facchi G, Cullurà D, Verri E, Rocca MC, Zurrida S, Iacovelli R, Nolè F. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer. Future Oncol 2016; 12:2001-8. [DOI: 10.2217/fon-2016-0081] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: To shed light on the clinical role of HER2 status in serum as extracellular domain (ECD) and corresponding circulating tumor cells (CTCs) in metastatic breast cancer patients. Methods: 68 patients were analyzed. Serum HER2 was determined by ADVIA Centaur® Serum HER2 test. CellSearch System was performed for CTC quantification. Results: HER2 was overexpressed in 21 primary tumors. In total, 19 patients had ECD >15 ng/ml (the cut-off used), 48 patients had at least one CTC. ECD positivity was associated with CTC number (p = 0.01), HER2-positive CTC (p = 0.01) and the ratio HER2-positive CTC/total CTC (p = 0.02). ECD was not associated with survival. Conclusion: ECD in combination with HER2 CTC status would deserve further investigation in larger series for addressing its putative prognostic relevance.
Collapse
Affiliation(s)
- Gaetano Aurilio
- European Institute of Oncology, Medical Oncology, via Ripamonti 435, Milan, Italy
| | - Maria Teresa Sandri
- European Institute of Oncology, Laboratory of Medicine, via Ripamonti 435, Milan, Italy
| | - Giancarlo Pruneri
- European Institute of Oncology, Division of Pathology & Laboratory Medicine, via Ripamonti 435, Milan, Italy & School of Medicine, University of Milan, Italy
| | - Laura Zorzino
- European Institute of Oncology, Laboratory of Medicine, via Ripamonti 435, Milan, Italy
| | - Edoardo Botteri
- European Institute of Oncology, Division of Epidemiology & Biostatistics, via Ripamonti 435, Milan
| | - Elisabetta Munzone
- European Institute of Oncology, Medical Oncology, via Ripamonti 435, Milan, Italy
| | - Laura Adamoli
- European Institute of Oncology, Medical Oncology, via Ripamonti 435, Milan, Italy
| | - Giuseppina Facchi
- European Institute of Oncology, Laboratory of Medicine, via Ripamonti 435, Milan, Italy
| | - Daniela Cullurà
- European Institute of Oncology, Medical Oncology, via Ripamonti 435, Milan, Italy
| | - Elena Verri
- European Institute of Oncology, Medical Oncology, via Ripamonti 435, Milan, Italy
| | - Maria Cossu Rocca
- European Institute of Oncology, Medical Oncology, via Ripamonti 435, Milan, Italy
| | - Stefano Zurrida
- European Institute of Oncology, Division of Senology, via Ripamonti 435, Milan, Italy
| | - Roberto Iacovelli
- European Institute of Oncology, Medical Oncology, via Ripamonti 435, Milan, Italy
| | - Franco Nolè
- European Institute of Oncology, Medical Oncology, via Ripamonti 435, Milan, Italy
| |
Collapse
|
4
|
Verri E, Aurilio G, Cossu Rocca M, Sandri M, Pruneri G, Botteri E, Zorzino L, Cassatella C, Adamoli L, Cullurà D, De Cobelli O, Musi G, Jereczek B, Iacovelli R, Nolè F. Clinical outcome of circulating tumor cells in metastatic castration-resistant prostate cancer patients treated with docetaxel: long-term prospective single-centre study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv341.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
5
|
Curigliano G, Bagnardi V, Bertolini F, Alcalay M, Locatelli MA, Fumagalli L, Rabascio C, Calleri A, Adamoli L, Criscitiello C, Viale G, Goldhirsch A. Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. Breast 2015; 24:263-71. [PMID: 25772326 DOI: 10.1016/j.breast.2015.02.036] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2014] [Revised: 02/10/2015] [Accepted: 02/22/2015] [Indexed: 11/30/2022] Open
Abstract
OBJECTIVES To assess efficacy of bevacizumab in combination with oral chemotherapy in patients with breast cancer with lymphangitic spread to the chest wall (LBC). To identify surrogate biomarkers of response to bevacizumab. PATIENTS AND METHODS We randomly assigned patients to receive bevacizumab plus either sequential or concurrent oral vinorelbine and capecitabine every 3 weeks. The primary endpoint was time to ultimate progression (TTP); the response rate and overall survival (OS) were secondary endpoints. We performed gene expression profiling on baseline tissue samples collected from triple negative LBC. We assessed circulating endothelial cells (CEC), circulating endothelial progenitors (CEP) and circulating pericyte progenitors (CPP). RESULTS A total of 66 patients were enrolled. There was no difference in TTP (median TTP 5.3 vs. 4.8 months, p = 0.21) and in OS (median OS 15.8 vs 11.9 months; p = 0.25) when comparing concurrent vs sequential treatment, respectively. Response rate was 25% vs 28% in the concurrent vs sequential arm (p = 1.00), respectively. A set of 16 genes predictive of response to bevacizumab was identified. The counts of CEPs and viable CECs below the median value were associated with an improved overall survival: 26.6 vs 9.5 months for CEPs and 22.6 vs 11.0 months for viable CECs, respectively (p = 0.02). CONCLUSIONS Oral chemotherapy and bevacizumab (BEVIX) is an active regimen in patients with LBC. We support the importance of using LBC as a biological model for investigating angiogenesis inhibitors. CECs and CEPs biomarkers have been identified as predictive markers of outcome and warrant further investigation.
Collapse
Affiliation(s)
- Giuseppe Curigliano
- Division of Experimental Therapeutics, Breast Health Program, Istituto Europeo di Oncologia, Italy.
| | - Vincenzo Bagnardi
- Division of Epidemiology and Biostatistics, Istituto Europeo di Oncologia, Italy; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milano, Italy
| | | | - Myriam Alcalay
- Department of Experimental Oncology, Italy; University of Milano, School of Medicine, Milano, Italy
| | - Marzia Adelia Locatelli
- Division of Experimental Therapeutics, Breast Health Program, Istituto Europeo di Oncologia, Italy
| | - Luca Fumagalli
- Division of Experimental Therapeutics, Breast Health Program, Istituto Europeo di Oncologia, Italy
| | | | | | - Laura Adamoli
- Division of Experimental Therapeutics, Breast Health Program, Istituto Europeo di Oncologia, Italy
| | - Carmen Criscitiello
- Division of Experimental Therapeutics, Breast Health Program, Istituto Europeo di Oncologia, Italy
| | - Giuseppe Viale
- Department of Pathology, Istituto Europeo di Oncologia, Italy; University of Milano, School of Medicine, Milano, Italy
| | - Aron Goldhirsch
- Division of Experimental Therapeutics, Breast Health Program, Istituto Europeo di Oncologia, Italy
| |
Collapse
|
6
|
Magni E, Botteri E, Ravenda PS, Cassatella MC, Bertani E, Chiappa A, Luca F, Zorzino L, Bianchi PP, Adamoli L, Sandri MT, Zampino MG. Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery. Int J Colorectal Dis 2014; 29:1053-9. [PMID: 25008360 DOI: 10.1007/s00384-014-1958-z] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/29/2014] [Indexed: 02/04/2023]
Abstract
PURPOSE Circulating tumor cells (CTCs) represent an independent prognostic factor in metastatic colorectal cancer, while their significance in early stages is still an open issue. The aim of the study is to investigate the role of CTCs in rectal cancer patients undergoing neoadjuvant chemoradiotherapy (CT-RT). METHODS In this prospective single institutional study, cT3-4 and/or N+ rectal cancer was treated with neoadjuvant CT-RT. The primary endpoints were as follows: evaluation of CTCs at baseline (t0), after CT-RT (t1), within 7 days after surgery (t2), and at 6 months from surgery (t3) and correlation with main patient/tumor characteristics, CEA, response to neoadjuvant therapy, and disease-free survival (DFS). CTCs were enumerated with the CellSearch System in 22.5 ml peripheral blood. A repeated measure analysis for binary outcome was used to evaluate over time changes in the percentage of CTCs detectable in blood samples. RESULTS Of the 90 patients enrolled in this study, 85 were eligible consisting of 52 males and 33 females. Median age was 63 years and median follow-up was 38 months. CTCs were available for all patients at t0, for 67 at t1, for 68 at t2, and for 62 at t3. CTCs >0 were reported on 16 (19%) at t0, on 5 (7.5%) at t1, on 6 (9%) at t2, and on 3 (5%) at t3 (P value for trend 0.039). Only for CT-RT responders, CTCs reduced from t0 to t1. No statistically significant association was found between CTCs and main patient/tumor characteristics and DFS. CONCLUSIONS Sixteen patients (19%) had CTCs ≥1 at t0 with reduction in CTC number in case of objective remissions. The proportion of patients with CTCs ≥1 decreased over the time as the therapeutic course proceeded. Much effort should be oriented toward increasing CTC detection rate by enhancing technical tests and achieving better patient characterization.
Collapse
Affiliation(s)
- Elena Magni
- Gastrointestinal and Neuroendocrine Tumors Unit, European Institute of Oncology, via Ripamonti 435, 20141, Milan, Italy,
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Criscitiello C, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Adamoli L, Goldhirsch A, Curigliano G. Immune approaches to the treatment of breast cancer, around the corner? Breast Cancer Res 2014; 16:204. [PMID: 25774617 PMCID: PMC3978442 DOI: 10.1186/bcr3620] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Immunotherapy for the treatment of breast cancer can be categorized as either (a) specific stimulation of the immune system by active immunization, with cancer vaccines, or (b) passive immunization, such as tumor-specific antibodies (including immune modulators) or adoptive cell therapy that inhibit the function of, or directly kill, tumor cells. We will present the current information and the future perspectives of immunotherapy in patients with breast cancer, including the prognostic role of tumor infiltrating lymphocytes, immune signatures, targeted therapies modulating the immune system, and tumor antigen cancer vaccines. Active immunotherapy in breast cancer and its implementation into clinical trials have been largely a frustrating experience in the last decades. The concept that the immune system regulates cancer development is experiencing a new era of interest. It is clear that the cancer immunosurveillance process indeed exists and potentially acts as an extrinsic tumor suppressor. Also, the immune system can facilitate tumor progression by sculpting the immunogenic phenotype of tumors as they develop. Cancer immunoediting represents a refinement of the cancer immunosurveillance hypothesis and resumes the complex interaction between tumor and immune system into three phases: elimination, equilibrium, and escape. Major topics in the field of immunology deserve a response: what do we know about tumor immunogenicity, and how might we therapeutically improve tumor immunogenicity? How can we modulate response of the immune system? Is there any gene signature predictive of response to immune modulators? The success of future immunotherapy strategies will depend on the identification of additional immunogenic antigens that can serve as the best tumor-rejection targets. Therapeutic success will depend on developing the best antigen delivery systems and on the elucidation of the entire network of immune signaling pathways that regulate immune responses in the tumor microenvironment.
Collapse
|
8
|
Rossi V, Nolè F, Redana S, Adamoli L, Martinello R, Aurilio G, Verri E, Sapino A, Viale G, Aglietta M, Montemurro F. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. Breast 2014; 23:44-9. [DOI: 10.1016/j.breast.2013.10.005] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2013] [Revised: 08/08/2013] [Accepted: 10/14/2013] [Indexed: 10/26/2022] Open
|
9
|
Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, Adamoli L, Munzone E, Sciandivasci A, De Vita F, Goldhirsch A, Nolè F. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer 2014; 50:277-89. [DOI: 10.1016/j.ejca.2013.10.004] [Citation(s) in RCA: 171] [Impact Index Per Article: 17.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2013] [Revised: 07/03/2013] [Accepted: 10/07/2013] [Indexed: 02/02/2023]
|
10
|
Catania C, Radice D, Spitaleri G, Adamoli L, Noberasco C, Delmonte A, Vecchio F, de Braud F, Toffalorio F, Goldhirsch A, De Pas T. The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study. Psychooncology 2013; 23:322-9. [DOI: 10.1002/pon.3424] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2013] [Revised: 09/06/2013] [Accepted: 09/11/2013] [Indexed: 01/29/2023]
Affiliation(s)
- C. Catania
- Clinical Pharmacology and New Drugs Development Division, Medical Oncology Department; European Institute of Oncology; Milan Italy
| | - D. Radice
- Epidemiology and Biostatistics Division; European Institute of Oncology; Milan Italy
| | - G. Spitaleri
- Clinical Pharmacology and New Drugs Development Division, Medical Oncology Department; European Institute of Oncology; Milan Italy
| | - L. Adamoli
- Clinical Pharmacology and New Drugs Development Division, Medical Oncology Department; European Institute of Oncology; Milan Italy
| | - C. Noberasco
- Clinical Pharmacology and New Drugs Development Division, Medical Oncology Department; European Institute of Oncology; Milan Italy
| | - A. Delmonte
- Clinical Pharmacology and New Drugs Development Division, Medical Oncology Department; European Institute of Oncology; Milan Italy
| | - F. Vecchio
- Clinical Pharmacology and New Drugs Development Division, Medical Oncology Department; European Institute of Oncology; Milan Italy
| | - F. de Braud
- Medical Oncology Unit 1; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - F. Toffalorio
- Clinical Pharmacology and New Drugs Development Division, Medical Oncology Department; European Institute of Oncology; Milan Italy
| | - A. Goldhirsch
- Department of Medicine; European Institute of Oncology; Milan Italy
| | - T. De Pas
- Clinical Pharmacology and New Drugs Development Division, Medical Oncology Department; European Institute of Oncology; Milan Italy
| |
Collapse
|
11
|
Munzone E, Botteri E, Rotmensz N, Cipolla CM, Zanelotti A, Adamoli L, Viale G, Goldhirsch A, Gandini S. Prognostic effect of beta blockers (BB) in triple-negative breast cancer (TNBC) patients. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.1061] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1061 Background: BB drugs have been used for decades worldwide, typically to treat hypertension and arrhythmias. Despite its therapeutic indication, evidence from recent epidemiological studies suggested that BB intake can improve prognosis of patients (pts) with cancer. With the present study we aimed at assessing whether BB intake is associated with improved prognosis in postmenopausal pts with TNBC, which represents one of the most aggressive cancers. Methods: We retrospectively identified 659 postmenopausal pts operated between 1997 and 2008 at the European Institute of Oncology, Milan, for a primary TNBC. Pts with advanced disease at diagnosis, presurgical systemic treatment or history of other cancers were excluded. The effect of BB intake on the risk of breast cancer recurrence and death from breast cancer (BC) was evaluated through competing risk survival analyses and multivariable Cox regression models. Results: At the time of cancer diagnosis, 61 pts (9.3%) out of 659 were currently using BB, while 598 (90.7%) were not. Median age was 63 years for the BB users and 60 years for the non-users (p value 0.048). All other characteristics—such as tumor size, lymph-nodal involvement, Ki-67, tumor grade, perivascular invasion, type of surgery and adjuvant therapy—were equally distributed between BB users and non-users. Median follow-up was 6 years for both groups. The 5-year cumulative incidence of BC recurrences was 11.7% and 24.1% for BB users and non-users, respectively (p = 0.030). After adjusting for age, tumor size, lymph nodal involvement, grade, perivascular invasion and use of other antihypertensive drugs, the beneficial impact of BB use remained statistically significant, with an hazard ratio of 0.44 (95% CI 0.21-0.98; p = 0.044). The 5-year cumulative incidence of BC deaths was 8.2% and 12.5% for BB users and non-users, respectively (p = 0.185). Hypertension and antihypertensive drugs other than BB did not have any significant impact on recurrence and survival. Conclusions: In this series of postmenopausal pts with primary TNBC, BB intake was associated with a significantly decreased risk of BC recurrence. Additional studies evaluating the potential benefits of BB on cancer prognosis are warranted.
Collapse
Affiliation(s)
| | | | - Nicole Rotmensz
- European Institute of Oncology, Division of Epidemiology and Biostatistics, Milan, Italy
| | | | | | - Laura Adamoli
- European Institute of Oncology, Data Management, Milan, Italy
| | | | - Aron Goldhirsch
- Division of Medical Oncology, European Institute of Oncology, Milan, Italy
| | | |
Collapse
|
12
|
Zampino MG, Magni E, Ravenda SP, Botteri E, Bertani E, Chiappa A, Valvo M, Zorzino L, Adamoli L, Nole F, Sandri MT. Detection of circulating tumor cells (CTCs) in stage T3-4 and/or N positive rectal cancer (RC) patients undergoing neoadjuvant therapy followed by curative surgery. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.e22078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22078 Background: CTCs count at baseline and during treatment is an independent prognostic factor in metastatic colorectal cancer, while its role in early stages is still an open issue. No data are available in RC patients suitable for neoadjuvant chemoradiotherapy (CT-RT). Aim of the study: To investigate the role of CTCs in patients with locally advancedRC undergoing neo-adjuvant CT-RT. Methods: In a prospective single Institution study, cT3-4 and/or N+RC staged by rectal EUS and/or pelvic MRI and chest-abdomen CT scan, received capecitabine (825 mg/mq, orally, tid) with concurrent pelvic radiotherapy (50.4 Gy/28 fractions), followed by two cycles of intermittent capecitabine (1250 mg/mq, tid 14/21 days) and by low anterior resection or abdominopelvic resection with TME. Primary endpoints are evaluation of CTCs at baseline (t0), after CT-RT (t1), within 7 days after surgery (t2), and at 6-month from surgery (t3) and its correlation with main patient/tumor characteristics, CEA and response to neoadjuvant therapy. CTCs are enumerated with CellSearch System in 22.5 ml peripheral blood at over-mentioned time-points. A repeated measure analysis for binary outcome was used to evaluate changes in time of the percentage of patients with CTCs>0. Results: 85/90 patients are evaluable: 52M/33F, median age 63 yrs (range 37-82); median follow up 25 months (range 6-52). At baseline (t0) 13 pts had 1 CTC (15.3%), two had 2 CTCs (2.4%) and one had 27 CTCs(1.2%) while in 69 cases (81.2%) no CTCs were detected. Information on CTCs was available for 67 patients at t1, 68 patients at t2 and 62 at t3. CTCs>0 was reported on 16 (18.8%) at t0, 5 (7.5%) at t1, 6 (8.8%) at t2 and 3 (4.8% ) at t3 (P-value for trend: 0.039). CTCs at t0 was not statistically associated with any patient/tumor characteristics except for ultrasound T-stage that showed a trend CTCs (0% in uT2, 18.9% in uT3 and 40% in uT4, p-value 0.093), while no correlation with pCR was reported. Conclusions: CTCs count ≥ 1 was observed in 18.8% of patients with trend reduction over time probably due to therapy. Statistical correlation will be planned between CTCs and outcome.
Collapse
Affiliation(s)
- M. Giulia Zampino
- VD Unità di Cure Mediche, Istituto Europeo di Oncologia, Milano, Italy
| | - Elena Magni
- Clinical Care Unit, European Institute of Oncology, Milan, Italy
| | | | | | | | | | | | | | - Laura Adamoli
- European Institute of Oncology, Data Management, Milan, Italy
| | - Franco Nole
- Unit for Medical Care, European Institute of Oncology, Milan, Italy
| | | |
Collapse
|
13
|
Munzone E, Casali C, Aurilio G, Botteri E, Perin A, Pelicci G, Brescia P, Sciandivasci A, Adamoli L, Viale G, DiMeco F. Outcome and clinico-biological characteristics of advanced breast cancer patients with surgically resected brain metastases: a multidisciplinary approach. Ecancermedicalscience 2013; 7:309. [PMID: 23634179 PMCID: PMC3634722 DOI: 10.3332/ecancer.2013.309] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2013] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND Despite improvements in brain surgery and radiotherapy, patients with brain metastases (BM) from breast cancer still have a poor prognosis. The aim of the present study is to evaluate the outcome of a multimodal therapeutic strategy in an unselected cohort of patients. METHODS We retrospectively reviewed 24 breast cancer patients who developed BM and were treated with brain surgery, radiotherapy, and/or systemic therapy in the same institutions. RESULTS Primary treatment for BM was surgery in the whole cohort, radiotherapy in 11 patients, radiotherapy combined with systemic therapy in nine patients, and systemic therapy as single treatment in six patients (chemo/targeted therapy n= 4; hormonal therapy n=2). The median time from breast cancer diagnosis to brain surgery was 57.6 months (range 1.8-130.7 months). The overall survival from surgery for BM was 22 months and the overall survival from BM surgery by presence of other metastatic sites at surgery was 25 months for patients with BM only and 11 months for patients with other metastatic sites (p=0.046). CONCLUSION Although this study is retrospective and limited by the small number of patients, the overall survival of 22 months from the time of brain surgery represents an excellent outcome. The multidisciplinary approach that combines the efforts of specialists from different disciplines leads to satisfactory results for patients in terms of survival in the current clinical practice and prospective subtype-oriented trials are urgently required in this category of patients.
Collapse
Affiliation(s)
- Elisabetta Munzone
- Department of Medicine, Division of Medical Senology, European Institute of Oncology, Milan, Italy
| | - Cecilia Casali
- Unità Operativa Neurochirurgia I, Istituto Neurologico Carlo Besta, Milan, Italy
| | - Gaetano Aurilio
- Department of Medicine, Division of Medical Senology, European Institute of Oncology, Milan, Italy
| | - Edoardo Botteri
- Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
| | - Alessandro Perin
- Unità Operativa Neurochirurgia I, Istituto Neurologico Carlo Besta, Milan, Italy
| | - Giuliana Pelicci
- Department of Experimental Oncology, European Institute of Oncology, Milan, Italy
| | - Paola Brescia
- Department of Experimental Oncology, European Institute of Oncology, Milan, Italy
| | - Angela Sciandivasci
- Department of Medicine, Division of Medical Senology, European Institute of Oncology, Milan, Italy
| | - Laura Adamoli
- Department of Medicine, Division of Medical Senology, European Institute of Oncology, Milan, Italy
| | - Giuseppe Viale
- Division of Pathology, European Institute of Oncology, Milan, Italy
- University of Milan, Milan, Italy
| | - Francesco DiMeco
- Unità Operativa Neurochirurgia I, Istituto Neurologico Carlo Besta, Milan, Italy
| |
Collapse
|
14
|
Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensz N, Aurilio G, Curigliano G, Goldhirsch A, Nolè F. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. Clin Breast Cancer 2013; 12:340-6. [PMID: 23040002 DOI: 10.1016/j.clbc.2012.07.001] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2012] [Revised: 05/25/2012] [Accepted: 07/09/2012] [Indexed: 11/19/2022]
Abstract
BACKGROUND Breast cancer is a heterogeneous disease. Circulating tumor cell (CTC) enumeration might be useful to identify different risk categories within each molecular subtype. METHODS We retrospectively analyzed 203 consecutive patients with metastatic breast cancer with baseline CTC enumeration performed with CellSearch (Veridex Corp, Warren, NJ) between March 2005 and July 2011. Patients were categorized into 3 prognostic groups based on the number of CTCs (0, 1-4, and ≥ 5) and into 5 categories based on tumor biological characteristics: luminal-A (estrogen receptor [ER] and progesterone receptor [PR] > 1%, grade 1/2, human epidermal growth factor 2 [HER2]-negative [HER2(-)], Ki67 value < 14%); luminal-B (ER and/or PR > 1%, grade 3, HER2(-), Ki67 value > 14%); luminal-B HER2-positive [HER2(+)] (ER and/or PR > 1%, any grade, HER2(+), Ki-67 value any); HER2(+) (HER2 overexpressed/fluorescence in situ hybridization [FISH] amplified, ER and PR absent); triple negative (TN) (ER and PR 0%, HER2 not overexpressed/FISH not amplified). RESULTS Median age was 57 years (range 31-78 years). Twenty-seven patients (13.3%) had luminal-A category, 105 (51.7%) patients had luminal-B, 29 (14.3%) patients had luminal-B HER2(+), 24 patients (11.8%) had HER2(+), and 18 patients (8.9%) had TN. CTCs were mostly found in patients with luminal-A/luminal-B HER2(-) subtype. At multivariable analysis, CTC count was a significant predictive factor for overall survival (OS) in all molecular subtypes (log-rank P < .01). Patients with 0 CTCs/7.5 mL blood and all subtypes, except HER2(+), seem to perform better compared with other categories. CONCLUSION These findings confirm CTCs as an important prognostic factor for metastatic breast cancer in all molecular subtypes. Larger studies could help identify metastatic breast cancer subgroups in which CTC analysis would be particularly useful.
Collapse
Affiliation(s)
- Elisabetta Munzone
- Division of Medical Oncology, Istituto Europeo di Oncologia, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Munzone E, Botteri E, Esposito A, Sciandivasci A, Franchi D, Pruneri G, Rotmensz N, Curigliano G, Adamoli L, Bocciolone L, Goldhirsch A, Nolé F. Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases. Ann Oncol 2012; 23:2884-2890. [PMID: 22547541 DOI: 10.1093/annonc/mds098] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Patients with metastatic breast cancer to the ovary, without tumor debulking and after systemic therapy, have a 5-year survival rate < 10%. PATIENTS AND METHODS We analyzed a series of 37 patients, operated in one institution over 10 years, for both the primary tumor (PT) and ovarian/pelvic metastases (OPM). Estrogen receptors (ER), progesterone receptors (PgR), HER-2 and Ki-67 were determined. RESULTS Patients were predominantly young: 27 (73%) patients were < 50 years. Average ER/PgR expression did not change significantly between PT (mean ER = 66%, PgR = 35%) and OPM (mean ER = 67%, PgR = 28%). Median time to OPM was 42 months (range 0-176); 5-year OS after OPM was 51% (95% confidence interval 32% to 67%). When combining ER and PgR status, patients with ER > 50% on both PT and OPM and with PgR > 50% on PT and/or OPM (good prognosis, 11 patients) had a better outcome versus0 patients with ER and PgR ≤ 50% on both PT and OPM (bad prognosis, eight patients) and also versus the remaining patients (intermediate prognosis, 18 patients), P value = 0.010. CONCLUSION Patients with OPM from breast cancer show a favorable prognosis after tumor debulking, whether it was radical or not, especially when a high expression of ER and PgR is present in both PT and OPM.
Collapse
Affiliation(s)
- E Munzone
- Department of Medicine, Division of Medical Oncology.
| | - E Botteri
- Division of Epidemiology and Biostatistics
| | - A Esposito
- Department of Medicine, Division of Medical Oncology
| | | | | | - G Pruneri
- Division of Pathology, Istituto Europeo di Oncologia, Milano, Italy
| | - N Rotmensz
- Division of Epidemiology and Biostatistics
| | - G Curigliano
- Department of Medicine, Division of Medical Oncology
| | - L Adamoli
- Department of Medicine, Division of Medical Oncology
| | | | - A Goldhirsch
- Department of Medicine, Division of Medical Oncology
| | - F Nolé
- Department of Medicine, Division of Medical Oncology
| |
Collapse
|
16
|
Aurilio G, Munzone E, Botteri E, Sciandivasci A, Adamoli L, Minchella I, Esposito A, Cullurà D, Curigliano G, Colleoni M, Goldhirsch A, Nolè F. Oral Metronomic Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort Report. Breast J 2012; 18:470-4. [DOI: 10.1111/j.1524-4741.2012.01278.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
Aurilio G, Disalvatore D, Bagnardi V, Munzone E, Adamoli L, Curigliano G, Pruneri G, Sciandivasci A, De Vita F, Goldhirsch A, Nole F. A meta-analysis of receptor status discordance between primary breast cancer and metastases. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.546] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
546 Background: There is an increasing awareness that biology of breast cancer may evolve over time. The discordance in estrogen (ER), progesterone (PgR) and HER2 receptor status between primary breast cancer and metastases is being intensively investigated and a large amount of data has been produced. However, results from different studies seem to be conflicting and heterogeneous. To highlight this issue, a meta-analysis of published data was performed. Methods: A literature search was performed with Medline. All studies published from 1983 to 2011 comparing changes inER, PgR and/or HER2 status in patients with matched breast primary and recurrent tumors were included. We used random-effects models to estimate pooled discordance proportions. Results: We selected 42 articles, mostly reporting retrospective studies. Twenty-eight, 20 and 27 articles were focused on ER, PgR and HER2 changes, respectively. A total of 2806 tumors were evaluated for ER discordance, 1809 for PgR discordance and 2801 for HER2 discordance. The heterogeneity between study-specific discordance proportions was high (I2 >75%, p<0.0001) for ER, PgR and HER2. Pooled discordance proportions were 20% (95% CI: 16-25%) for ER, 33% (95% CI: 28-38%) for PgR and 9% (95% CI: 6-12%) for HER2. Pooled proportions of tumors shifting from positive to negative and from negative to positive were 24% and 12% for ER (p=0.0115), respectively. The same figures were 44% and 15% for PgR (p<0.0001), and 14% and 6% for HER2 (p=0.04). Conclusions: To our knowledge, this is the first meta-analysis addressing this topic. The findings strengthen the concept that changes in receptor expression may occur during the natural history of breast cancer and therefore clinical implications with possible impact on treatment choice cannot be excluded. However, the high heterogeneity observed in our analysis may explain the disagreement among oncologists on performing a reassessment of the biological features. In our opinion, only high-powered prospective and randomized trials could clarify the controversies in this field.
Collapse
Affiliation(s)
- Gaetano Aurilio
- European Institute of Oncology, Medical Oncology, Milan, Italy
| | - Davide Disalvatore
- European Institute of Oncology, Division of Epidemiology and Biostatistics, Milan, Italy
| | - Vincenzo Bagnardi
- European Institute of Oncology, Division of Epidemiology and Biostatistics, Milan, Italy
| | | | - Laura Adamoli
- European Institute of Oncology, Data Management, Milan, Italy
| | - Giuseppe Curigliano
- Department of Medicine, Division of Medical Oncology, Istituto Europeo di Oncologia, Milan, Italy
| | | | | | - Fernando De Vita
- Medical Oncology Division, Second University of Naples, Naples, Italy
| | - Aron Goldhirsch
- European Institute of Oncology, Medical Oncology, Milan, Italy
| | - Franco Nole
- European Institute of Oncology, Medical Oncology, Milan, Italy
| |
Collapse
|
18
|
Munzone E, Botteri E, Bagnardi V, Sciandivasci A, Aurilio G, Adamoli L, Esposito A, Rotmensz N, Goldhirsch A, Nole F. A prognostic model for predicting breast cancer (BC)-related survival in operable triple-negative (TN) patients (pts). J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.1049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1049 Background: TNBC represent a heterogeneous disease in terms of biology, prognosis, and treatment response. We propose a prognostic model to identify homogeneous subgroups of patients and tailor risk-adapted adjuvant therapies indications. Methods: We analyzed 1,049 pts operated in our institute from 1997 to 2007 for early TNBC. Pts who received neoadjuvant chemotherapy (CT), with T4 tumors or previous history of cancer were excluded. Death from BC was the primary endpoint of the study. We calculated an individual predicted risk using a multivariable Cox regression model, with age, tumor size, number of positive lymph nodes and Ki-67 analyzed as continuous covariates, and tumor grade and perivascular invasion as categorical covariates. Results: Median age was 52 years, 562 (53.4%) and 670 (65.1%) pts had a pT1 and pN0 TNBC, respectively. Median Ki-67 was 48%. Adjuvant CT regimens were distributed as follows: classical CMF 388 (37.0%), anthracycline containing regimens 455 (43.4%), taxanes 12 (1.1%), other regimens 66 (6.3%) and no CT 128 (12.2%). After a median follow-up of 6 years, 131 deaths from BC were observed (5-year cumulative incidence 11.9%). At multivariable analysis, age, tumor size, number of positive lymph nodes, Ki-67, tumor grade and perivascular invasion were associated with the risk of death and were included in the prognostic model. Its predictive accuracy was good (C-index 0.73). We subsequently identified three homogeneous prognostic subgroups - low, medium and high-risk - according to the tertiles values of the predicted risk. The outcomes are shown in the table. Conclusions: We could identify homogeneous prognostic subgroups of TNBC pts according to clinical-pathological features. This prognostic model suggests that the use of CT in TN low-risk pts might be questionable. We are currently externally validating this model on a different series of pts. [Table: see text]
Collapse
Affiliation(s)
| | - Edoardo Botteri
- European Institute of Oncology, Division of Epidemiology and Biostatistics, Milan, Italy
| | - Vincenzo Bagnardi
- European Institute of Oncology, Division of Epidemiology and Biostatistics, Milan, Italy
| | | | - Gaetano Aurilio
- European Institute of Oncology, Medical Oncology, Milan, Italy
| | - Laura Adamoli
- European Institute of Oncology, Data Management, Milan, Italy
| | - Angela Esposito
- European Institute of Oncology, Medical Oncology, Milan, Italy
| | - Nicole Rotmensz
- European Institute of Oncology, Division of Epidemiology and Biostatistics, Milan, Italy
| | - Aron Goldhirsch
- European Institute of Oncology, Medical Oncology, Milan, Italy
| | - Franco Nole
- European Institute of Oncology, Medical Oncology, Milan, Italy
| |
Collapse
|
19
|
Botteri E, Munzone E, Bagnardi V, Intra M, Rotmensz N, Bazolli B, Montanari B, Aurilio G, Sciandivasci A, Esposito A, Pagani G, Adamoli L, Nole F, Goldhirsch A. Role of breast surgery in T1-T3 breast cancer patients with synchronous bone metastases. J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.15_suppl.1115] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1115 Background: The role of breast surgery in advanced breast cancer (ABC) is controversial. The main potential advantage of removing the primary tumor is to eliminate the source of further metastatic spread. While previous studies addressed the question in very heterogeneous populations (e.g. patients with any local and distant extension), we have focused on a homogeneous series of ABC patients. Methods: From our institutional Tumor Registry we selected 191 consecutive women diagnosed between 2000 and 2008 with locally operable (T1-T3) ABC, synchronous bone metastases and no other distant sites involved. The progression free survival (PFS) was calculated from diagnosis to the date of progression, defined as either a new site of metastatic disease or clinical/radiographic evidence of increasing tumor burden at a previously known bone metastatic site. Results: Median age was 51 years and 92% of the women had an endocrine-responsive tumor. One-hundred and thirty patients out of 191 (68%) underwent surgery at the time of diagnosis, while 61 (32%) did not. Twenty-six of the operated patients (20%) had previously undergone neoadjuvant chemotherapy; 15 (12%) had positive or undetermined surgical margins. Operated and non-operated patients were similar with respect to age, tumor size, nodal involvement, estrogen and progesterone receptor status, HER2 overexpression and Ki-67, but differed in terms of number of bone metastatic sites: a single metastasis was detected in 34 (26%) operated and 7 (11%) non-operated cases (P=0.02). First-line treatment strategies with endocrine therapy, chemotherapy and Trastuzumab were similarly distributed between the two groups. The 5-year PFS was 22.0% and 10.4% in operated and non-operated patients, respectively. The multi-adjusted hazard ratio was 0.62 (95% confidence interval 0.39-0.98) in favor of surgery. The exclusion of the patients who had received neoadjuvant chemotherapy and patients with positive or undetermined surgical margins did not alter the results. Conclusions: In this large and homogeneous series of ABC patients with synchronous bone metastases, the role of breast surgery had a favorable impact on the progression of the disease, indicating a potential survival benefit.
Collapse
Affiliation(s)
- Edoardo Botteri
- European Institute of Oncology, Division of Epidemiology and Biostatistics, Milan, Italy
| | | | - Vincenzo Bagnardi
- European Institute of Oncology, Division of Epidemiology and Biostatistics, Milan, Italy
| | - Mattia Intra
- European Institute of Oncology, Division of Senology, Milan, Italy
| | - Nicole Rotmensz
- European Institute of Oncology, Division of Epidemiology and Biostatistics, Milan, Italy
| | - Barbara Bazolli
- European Institute of Oncology, Division of Epidemiology and Biostatistics, Milan, Italy
| | - Bruno Montanari
- European Institute of Oncology, Division of Epidemiology and Biostatistics, Milan, Italy
| | - Gaetano Aurilio
- European Institute of Oncology, Medical Oncology, Milan, Italy
| | | | - Angela Esposito
- European Institute of Oncology, Medical Oncology, Milan, Italy
| | | | - Laura Adamoli
- European Institute of Oncology, Data Management, Milan, Italy
| | - Franco Nole
- European Institute of Oncology, Medical Oncology, Milan, Italy
| | - Aron Goldhirsch
- European Institute of Oncology, Medical Oncology, Milan, Italy
| |
Collapse
|
20
|
Aurilio G, Munzone E, Botteri E, Pedroli S, Sandri M, Adamoli L, Zorzino L, Sciandivasci A, Esposito A, Nolè F. 41P Circulating Tumor Cells (CTCs) and Metronomic Oral Vinorelbine (OV) in Advanced Breast Cancer (ABC) Patients (PTS): Exploratory Prospective Analysis. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(19)65694-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
21
|
cossu Rocca M, Verri E, Blotta S, Adamoli L, Radice D, Riva DF, Nole F. Metastatic renal cell carcinoma (mRCC) in elderly patients: Can a personalized approach be an effective therapeutic option? J Clin Oncol 2012. [DOI: 10.1200/jco.2012.30.5_suppl.468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
468 Background: Renal cell carcinoma (RCC) is the third most common genitourinary cancer. Up to 30% of patients (pts) with RCC presents with advanced disease. Sunitinib(S), an orally available tyrosine kinase inhibitor, is the well established first-line therapy for these population. Actually few data are available in the literature about its use in patients > 75 yrs investigating the feasibility, the efficacy and the toxicity in this population. Methods: From 2007 to 2011, 16 pts >75 yrs with mRCC received S. 75% of pts had a clear cell carcinoma, 87.5% had a surgery on primary tumor, 18.7% had a metastic disease at diagnosis and the median time to metastatic progression was 13.5 months. Median age was 78 years (range 71-88y).All patients had 0-1 performance status and 69% of them received S as first-line treatment. Four pts started S on the approved 50 mg /d 4-week-on-2-off schedule, but three of them reduced to 37.5 mg continuous once daily dosing(ODD)starting from the third cycle. Five out of 8 pts receiving 37.5 mg continuous ODD reduced the dose at 25 mg continuous ODD or modified the schedule. Four pts started with 25 mg continuous ODD and 2 of them continued the treatment at modified schedule. Median number of cycles administered was 7 (range 2-16). Results: Response rate was 87% (13pts) in 15 evaluable pts. Overall response included 40% (6 pts) of PR, 20% (3pts) of CR, 33% (5pts) of SD > 6 mos. Progressive disease was observed only in 1patient. TTP was 12.4 months (95% CI, 4.8-32.6). Overall survival was 34.2 months (95% CI, 27.3- ). The main toxicity requiring dose reduction or schedule modification was haematological (46%), G3Anemia in 1 pt G3-4 thrombocytopenia in 3pts and G3 leukoneutrophenia in 3pts. No any toxicity required treatment interruption. Conclusions: In summary these results show the feasibility and the efficacy of S in elderly population with high response rate regardless the doses and schedule used.
Collapse
Affiliation(s)
| | - Elena Verri
- European Institute of Oncology, Milan, Italy
| | | | | | | | | | - Franco Nole
- European Institute of Oncology, Milan, Italy
| |
Collapse
|
22
|
Catania C, De Pas T, Minchella I, De Braud F, Micheli D, Adamoli L, Spitaleri G, Noberasco C, Milani A, Zampino MG, Toffalorio F, Radice D, Goldhirsch A, Nolè F. "Waiting and the waiting room: how do you experience them?" emotional implications and suggestions from patients with cancer. J Cancer Educ 2011; 26:388-394. [PMID: 20204572 DOI: 10.1007/s13187-010-0057-2] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/02/2009] [Accepted: 01/22/2010] [Indexed: 05/28/2023]
Abstract
Waiting can increase discomfort. The goal of this study was to identify moods and fears of cancer patients while in a waiting room and to capture their concrete suggestions for an anthropocentric transformation of waiting itself. A 15-item questionnaire was given to 355 patients who came to our Out-patient Oncology Clinic. Eighty-three percent of patients felt that waiting has an emotional cost, 35% were upset by talking about their condition with others while waiting, and 26% suffered a major emotional impact seeing other sick people and witnessing their clinical decline. Eighty-nine percent of patients suggested that alternative activities, such as meetings with professionals, doctors, and psychologists, be organized during the waiting period; 65% suggested fun activities (music therapy, drawing courses, library, TV). Most patients asked to have the freedom to leave the waiting room. This option, feasibly by means of IMs/"beepers," would limit their sense of having a lack of freedom or being robbed of their time. This study highlighted the complexity and heterogeneity of emotional implications that waiting causes in patients with cancer and collected many patients' suggestions about how to create a constructive, free, and personalized waiting period, overcoming the boredom, distress, and psychological suffering it causes.
Collapse
Affiliation(s)
- Chiara Catania
- Division of Clinical Pharmacology and New Drugs, European Institute of Oncology, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Montemurro F, Rossi V, Cossu Rocca M, Martinello R, Verri E, Redana S, Adamoli L, Valabrega G, Sapino A, Aglietta M, Viale G, Goldhirsch A, Nolè F. Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer 2011; 118:17-26. [DOI: 10.1002/cncr.26162] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2010] [Revised: 02/09/2011] [Accepted: 03/07/2011] [Indexed: 01/24/2023]
|
24
|
Munzone E, Nolé F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, Curigliano G, Minchella I, Adamoli L, Cassatella MC, Casadio C, Sandri MT. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer 2011; 10:392-7. [PMID: 20920984 DOI: 10.3816/cbc.2010.n.052] [Citation(s) in RCA: 81] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND HER2/neu status of tumor cells at metastatic sites in patients with advanced disease may differ from that of the primary tumor. Assessing the presence of target antigens on circulating tumor cells (CTCs) might affect treatment choice. PATIENTS AND METHODS From June 2007 to October 2008, we collected 23 mL of blood from each of the 76 consecutive patients before and during chemotherapy to determine CTC numbers and HER2 overexpression. CTCs were isolated with the CellSearch System® (Veridex, LLC; Raritan, NJ) and fluorescently stained with the Epithelial Cell Kit®. Tumor Phenotyping Reagent® was used to investigate HER2/neu overexpression. RESULTS Concordance of HER2 status between the primary tumor and CTCs was 86% (49 out of 57 patients) at baseline and 82% (50 out of 61 patients) in the treatment samples. HER2 overexpression in CTCs was acquired in 8 out of 45 patients (18%) and lost in 3 out of 16 patients (19%) during a treatment containing trastuzumab. The overall discordance rate between the primary tumor and CTCs was 18% (11 out of 61 patients). Patients with HER2 overexpression in CTCs had poorer progression-free survival compared with those without CTCs or with HER2- CTCs (log-rank P =.036). CONCLUSION Information on the presence or absence of HER2 overexpression can be obtained in CTCs. Larger trials are needed to evaluate the activity of HER2-targeted therapy in patients with acquired HER2 overexpression in CTCs.
Collapse
Affiliation(s)
- Elisabetta Munzone
- Division of Medical Oncology, European Institute of Oncology, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Montemurro F, Rossi V, Cossu Rocca M, Martinello R, Verri E, Redana S, Adamoli L, Valabrega G, Sapino A, Aglietta M, Viale G, Goldhirsch A, Nolè F. Abstract PD10-07: Hormone-Receptor Expression and Activity of Trastuzumab-Based Therapy in HER2-Positive Advanced Breast Cancer Patients. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-pd10-07] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Hormone receptors (HR) and the human epidermal growth factor receptor 2 (HER2) are key biological factors in breast cancer. Gene expression profile studies indicate that HER2-positive/HR-positive and HER2-positive/HR-negative tumors fall into two distinct subtypes. These two subtypes carry a different prognosis in the absence of HER2-targeting. Furthermore, a relationship has been documented between increasing HR expression and reduced chemoresponsiveness. Despite these differences, HER2-positive abvanced breast cancer patients are usually treated with a unified approach of combining chemotherapy with an HER2-targeting agent, regardless of HR status. We studied the association between hormone receptor (HR) expression and the clinical outcome of women with HER2-positive advanced breast cancer receiving chemotherapy plus trastuzumab.
Methods: The effect of HR expression on overall response rate (ORR) and progression-free survival (PFS) to trastuzumab-based treatment was studied by univariate and multivariate analysis. HR positivity was defined as 1% or more tumor cells positive for the estrogen (ER) and/or for the progesterone (PgR) receptor by immunohistochemistry. For both ER and PgR, we studied different thresholds to identify levels of expression associated with the clinical outcomes of interest.
Results: 227 consecutive advanced breast cancer patients receiving trastuzumab plus chemotherapy between June 1999 and November 2008 at two Institutions were retrospectively analyzed. One hundred eleven patients (49%) had HR-positive tumors. Compared with low or no expression, high expression of ER (30% or more) predicted reduced probability of tumor response to trastuzumab plus chemotherapy (multivariate odds ratio 0.422, 95% confidence interval-C.I. 0.222-0.803, p = 0.009). In patients with HR-positive tumors the addition of maintenance endocrine therapy to trastuzumab after the completion of chemotherapy was associated with a significant increase in progression-free survival (hazard ratio-HR 0.521, 95% C.I. 0.3325-0.836, p = 0.007). Patients with HR-positive tumors not receiving maintenance endocrine therapy had similar PFS than patients with HR-negative tumors (HR 0.914, 95% C.I. 0.654-1.279, p = 0.601). In patients not receiving maintenance endocrine therapy, high ER expression (30% or more cells) was associated with non-significant trend towards reduced risk of progression, compared with patients with low or absent ER expression (HR 0.747, 95% C.I. 0.516-1.081, p = 0.122). Conclusions: Our results suggest a predictive role of HR expression in HER2-positive tumors. Further investigation in this patient subset is warranted to optimize the use of HER2-targeting agents, chemotherapy and endocrine therapy.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD10-07.
Collapse
Affiliation(s)
- F Montemurro
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - V Rossi
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - M Cossu Rocca
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - R Martinello
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - E Verri
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - S Redana
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - L Adamoli
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - G Valabrega
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - A Sapino
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - M Aglietta
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - G Viale
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - A Goldhirsch
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| | - F. Nolè
- Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Turin, Italy; European Institute of Oncology, Milan, Italy; University of Turin, Italy
| |
Collapse
|
26
|
Sciandivasci A, Munzone E, Aurilio G, Adamoli L, Botteri E, Locatelli M, Esposito A, Minchella I, Cullura’ D, Curigliano G, Goldhirsch A, Nole’ F. Abstract P6-11-14: Long-Term Disease Control with Vinorelbine, Cisplatin and Continuous Infusion of 5-Fluorouracil -ViFuP Regimen-in Metastatic Triple Negative Breast Cancer Patients. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p6-11-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple negative breast cancers (TNBCs) are characterized by lack of estrogen, progesterone, HER-2-neu receptors expression and comprise 15% to 20% of all breast cancers. Studies have suggested that
TNBCs may be more sensitive to DNA damaging agents like cisplatin. Our previous experience had identified a combination chemotherapy -the ViFuP regimen-with noteworthy efficacy and safety as a first or subsequent line treatment for metastatic breast cancer (MBC) patients (pts). In this view we retrospectively examined the activity of ViFuP regimen in 2 cohorts (A and B) of metastatic TNBC pts.
Material and Methods: From January 2000 to December 2008, 115 pts with MBC were treated with ViFuP regimen, at the European Institute of Oncology, Milan, Italy. Among these, 35 pts (30%) had TNBC. Pts received continuous infusion 5-fluorouracil 200 mg/m2/day, vinorelbine 20 mg iv on days 1 and 3 and cisplatin 60 mg/m2on day 1. Therapy was given every three weeks. In A 22 pts (63%) were triple negative on primary tumor and in B 13 pts (37%) were triple negative in metastatic site. Median age was 54 years (range 35-73), 11 pts (31%) were pre-treated for MBC and 21 pts (60%) had ≥3 metastatic sites.
Results: Thirty three pts were evaluable for response and 34 pts were assessable for toxicity. Median duration of treatment was 3.57 months (range 1-5.7). Four pts (12%) had complete responses, 14 pts (42%) had partial responses and 11 pts (33%) had stable disease with a clinical benefit (CB) of 73% (95% CI, 55%-87%). Four pts (12%) had progressive disease. Median time to progression was 6 months (95% CI, 5-8 months). Main toxicity was haematological with 62% of the pts showing grade 3/4 leuco-neutropenia. Alopecia was almost absent.
Discussion: Treatment with ViFuP regimen was effective and safe in metastatic TNBC providing long-term disease control in a high proportion of pts. The prolonged CB supports this regimen as an additional therapeutic opportunity in this category of pts.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-11-14.
Collapse
Affiliation(s)
| | - E Munzone
- European Institute of Oncology, Italy
| | - G Aurilio
- European Institute of Oncology, Italy
| | - L Adamoli
- European Institute of Oncology, Italy
| | - E Botteri
- European Institute of Oncology, Italy
| | | | | | | | | | | | | | - F. Nole’
- European Institute of Oncology, Italy
| |
Collapse
|
27
|
Catania C, De Pas TM, Goldhirsch A, Spitaleri G, Noberasco C, Delmonte A, Radice D, Adamoli L, Vecchio F, De Braud FG. Increasing awareness of patients with cancer faced with the choice of whether to participate in a phase I clinical trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Curigliano G, Spitaleri G, Magni E, Lorizzo K, De Cobelli O, Locatelli M, Fumagalli L, Adamoli L, Cossu Rocca M, Verri E, De Pas T, Jereczek-Fossa B, Martinelli G, Goldhirsch A, Nolè F. Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study. J Chemother 2010; 21:687-92. [PMID: 20071294 DOI: 10.1179/joc.2009.21.6.687] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
We retrospectively reviewed medical charts of 54 patients who underwent orchidectomy for germ cell tumors (GCT) and received a regimen, given every 3 weeks, consisting of cisplatin 100 mg/m2 day 4 intravenous (i.v.), bleomycin 15 Units (U) day 1 i.v. push; bleomycin 10 U days 1-3 24 h i.v. continuous infusion (c.i.) and etoposide 100 mg/m2 days 1-5/i.v. (PEB). 53 of 54 patients achieved a complete remission without adjunctive surgery. At a median follow-up of 48.2 months (95%CI 41.7 - 54.8 months) all patients but one are alive with no evidence of disease recurrence. Patients receiving PEB experienced no pulmonary toxicity, nephrotoxicity nor neurological adverse events. PEB with c.i.bleomycin is an active regimen with a low rate of acute and late toxicity. The main limitations of our study are related to the retrospective analysis, the limited number of patients and the restricted follow-up time. A prolonged follow-up is necessary to evaluate long term toxicity and outcome.
Collapse
Affiliation(s)
- G Curigliano
- Division of Medical Oncology, Università di Milano, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Sandri MT, Zorzino L, Cassatella MC, Bassi F, Luini A, Casadio C, Botteri E, Rotmensz N, Adamoli L, Nolè F. Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery. Ann Surg Oncol 2010; 17:1539-45. [PMID: 20135356 DOI: 10.1245/s10434-010-0918-2] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2009] [Indexed: 02/06/2023]
Abstract
BACKGROUND Few data exist on the potential role of circulating tumor cells (CTCs) in patients with operable breast cancer. If the presence of CTCs in early breast cancer could predict an increased risk for relapse, it might be an early marker for treatment efficacy and could help in deciding treatment continuation. METHODS Thirty milliliters of peripheral blood was taken from 56 breast cancer patients before surgery and again 5 days after surgery, and the presence of CTCs was evaluated. In case of positivity of one of the perioperative samples, another sample was taken after 30 days. The presence of CTCs was assessed with the CellSearch System (Veridex, Warren, NJ). RESULTS One to three CTCs were found in 16 (29%) of 56 patients before surgery, in 14 (30%) of 47 patients at day 5, and in 8 (30%) of 27 at day 30. No association with pathological characteristics was found, apart a borderline significant association between presence of CTCs at baseline and vascular invasion (P = 0.07). When we looked at concordance between CTCs at baseline and after day 5 (47 patients), we found 40% discordant samples (10 negative at baseline and positive at day 5, and 9 vice versa). CONCLUSIONS This study provides evidence of the presence of CTCs in approximately 30% of patients with localized breast cancer both before and after surgery, with change from positive to negative and vice versa in 40% of cases. No association with the pathological variables was found, except for vascular invasion and presence of preoperative CTCs. Long-term follow-up will be required to understand the significance of these data.
Collapse
Affiliation(s)
- Maria T Sandri
- Unit of Laboratory Medicine, European Institute of Oncology, Via Ripamonti 435, Milan, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Munzone E, Di Pietro A, Goldhirsch A, Minchella I, Verri E, Cossu Rocca M, Marenghi C, Curigliano G, Radice D, Adamoli L, Nolè F. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: A mono-institutional case-series report. Breast 2010; 19:33-7. [DOI: 10.1016/j.breast.2009.10.003] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2009] [Revised: 10/02/2009] [Accepted: 10/06/2009] [Indexed: 12/20/2022] Open
|
31
|
Nole F, Munzone E, Bertolini F, Sandri MT, Petralia G, Adamoli L, Radice D, Cullura D, di Pietro A, Goldhirsch A. Circulating endothelial cells (CECs), progenitors (CEPs), and circulating tumor cells (CTCs) for prediction of response in patients with advanced breast cancer (ABC) receiving metronomic oral vinorelbine (oV): Preliminary results. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e14572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14572 Background: Metronomic administration of chemotherapy given once or more per week with no extended gaps was shown to be effectively anti-angiogenic, causing growth arrest or apoptosis of endothelial cells in tumor neo-vessels. Preclinical and clinical studies indicate that ultra-low concentrations of various microtubule inhibitors inhibit proliferation or migration of endothelial cells. We investigated in a phase II study the activity of metronomic administration of oV in ABC, kinetics and response prediction of CECs, CEPs, CTCs and of other biomarkers of angiogenesis (soluble VEGF, VEGFr2, TSP1, bFGF). CT perfusion scans were also performed. Methods: From February 2008, 47 pts with ABC received oV (50 mg/die TTW). Currently 20 pts are evaluable for both activity and biomarker assessment. Baseline levels of biomarkers of angiogenesis were correlated with clinical response. Results: Shown in Table . Conclusions: We found that the baseline value of apoptotic cells (expressed as % of total cells) was significantly correlated with outcome. The baseline total, viable, and apoptotic CEC count and CTCs might provide an indirect measure for angiogenic turnover and an indicator of better response to anti-angiogenic therapy, supporting the use of metronomic treatments in patients expressing high levels of baseline CECs. Updated results will be presented together with correlation with perfusion CT scan and levels of CTCs. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- F. Nole
- European Institute of Oncology, Milan, Italy
| | - E. Munzone
- European Institute of Oncology, Milan, Italy
| | | | | | - G. Petralia
- European Institute of Oncology, Milan, Italy
| | - L. Adamoli
- European Institute of Oncology, Milan, Italy
| | - D. Radice
- European Institute of Oncology, Milan, Italy
| | - D. Cullura
- European Institute of Oncology, Milan, Italy
| | | | | |
Collapse
|
32
|
Sandri MT, Zorzino L, Munzone E, Cassatella C, Luini A, Bassi F, Salvatici M, Botteri E, Rotmensz N, Esposito A, Adamoli L, Goldhirsch A, Nolè F. Circulating tumor cells in operable breast cancer: a pilot study. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-5028] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #5028
Background. Circulating tumor cells (CTCs) in the peripheral blood are an ideal source for the detection of disseminated tumor cells because of an easy sampling procedure. Their prognostic significance has been demonstrated in metastatic breast cancer, while little data exist in operable patients. Aims of this study are the evaluation of the prevalence and kinetics of CTCs before and after surgical treatment and the possible correlation between CTCs and clinico-pathological characteristics and biological features. Methods. We analyzed 30 ml of peripheral blood from 60 T1-T3, any N, M0 breast cancer pts, before surgery and after 5 days. In case of positivity of one of the perioperative samples, a further sample was taken after 30 days. The presence of CTCs was assessed with the CellSearch System (Veridex, USA). Samples were subjected to immunomagnetic enrichment with an anti-Epcam-antibody: CTCs were defined as nucleated cells expressing cytokeratin 8, 18 and 19 but lacking CD45. A sample was considered positive when 1 or more cells were detected. Results. Data are available for 50 pts. We found ≥1 CTC in 28% of the pts (n=14/50) before surgery, and in 29% of the patients (n= 12/42 ) at 5 days. The median number of CTCs was 1, with a range of 1-3. We found a borderline significant association between the presence of CTCs at baseline and the presence of vascular invasion (p=0.09). The presence of CTCs at baseline did not correlate with tumor size (p=0.66), grading (p=0.88), presence of estrogens receptor (p=0.30), presence of progesteron receptor (p=0.30), HER2/neu status of the tumor (p=1.0), or with the presence of lymph node metastases (p=0.71). In 42 pts we have the data of CTCs determined at baseline and at day 5: 27 patients showed concordant results (23 negative and 4 positive). Among the 15 patients with different results, 8 were negative at baseline and positive at day 5: 6 out of the 8 patients had positive nodes. At day 30 we analyzed samples from 18 subjects: persistence of at least 1 CTC was found in 18 % of patients (n=5). Conclusions. The results of this explorative study are very preliminary and a larger number of patients and a long-term follow-up will be required. However, it is of interest the borderline correlation between presence of CTCs at baseline and vascular invasion, and between appearance of CTCs and nodal involvement in postoperative samples. The study is ongoing and the patients will be followed during and after adjuvant treatment to explore the prognostic significance of persistency of CTCs. Complete data will be presented.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 5028.
Collapse
Affiliation(s)
- MT Sandri
- 1 Laboratory Medicine Unit, European Institute of Oncology, Milan, Italy
| | - L Zorzino
- 1 Laboratory Medicine Unit, European Institute of Oncology, Milan, Italy
| | - E Munzone
- 5 Unit for Medical Care, European Institute of Oncology, Milan, Italy
| | - C Cassatella
- 1 Laboratory Medicine Unit, European Institute of Oncology, Milan, Italy
| | - A Luini
- 3 Division of Senology, European Institute of Oncology, Milan, Italy
| | - F Bassi
- 3 Division of Senology, European Institute of Oncology, Milan, Italy
| | - M Salvatici
- 1 Laboratory Medicine Unit, European Institute of Oncology, Milan, Italy
| | - E Botteri
- 4 Department of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
| | - N Rotmensz
- 4 Department of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
| | - A Esposito
- 5 Unit for Medical Care, European Institute of Oncology, Milan, Italy
| | - L Adamoli
- 5 Unit for Medical Care, European Institute of Oncology, Milan, Italy
| | - A Goldhirsch
- 2 Department of Medicine, European Institute of Oncology, Milan, Italy
| | - F Nolè
- 5 Unit for Medical Care, European Institute of Oncology, Milan, Italy
| |
Collapse
|
33
|
Catania C, De Pas T, Goldhirsch A, Radice D, Adamoli L, Medici M, Verri E, Marenghi C, de Braud F, Nolè F. Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choice. Oncology 2008; 74:177-87. [PMID: 18714166 DOI: 10.1159/000151365] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2008] [Accepted: 03/26/2008] [Indexed: 11/19/2022]
Abstract
BACKGROUND Patients invited to take part in a clinical trial may evoke an archetype on which they may base their decision of adherence to participation, instead of on the study itself. METHODS A 17-item, multiple choice questionnaire was developed, tested and then administered to 102 Italian-speaking patients with advanced lung or breast cancers who had never been exposed to participation in a trial. RESULTS The questionnaire was answered by all patients. Eighty-five percent were positive about trial participation. Demographic factors did not influence patients' willingness to participate. Trust in the investigator (76%) or in the institute (64%) and hope of receiving a new chance for cure (78%) were cited as reasons to accept participation. A minority was concerned by potential conflicts of interest (31%) or the thought of being 'guinea pigs' (36%), and feared that doctors were interested in advancing their own research, even though there were more efficient drugs available (28%). Fifty percent feared receiving a little-known medicine, and 76% considered that a thorough explanation of toxicity/safety of the proposed treatment helped them decide. CONCLUSION Several prejudices, fears and some hopes have been captured by the questionnaire. Understanding such specifics will improve patient information leading patients to a more conscious motivation in deciding whether to participate in a clinical trial.
Collapse
Affiliation(s)
- Chiara Catania
- Division of Medical Oncology, European Institute of Oncology, Milan, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Catania C, Zagonel V, Fosser V, La Verde N, Bertetto O, Iacono C, Venturini M, Radice D, Adamoli L, Boccardo F. Opinions concerning euthanasia, life-sustaining treatment and acceleration of death: results of an Italian Association of Medical Oncology (AIOM) survey. Ann Oncol 2008; 19:1947-54. [PMID: 18556665 DOI: 10.1093/annonc/mdn381] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Advance directives, acceleration of death, euthanasia and 'life-sustaining treatment' have sparked much heated debate among the media, the public, doctors and political leaders. We evaluate the personal opinions of Italian Association of Medical Oncology (AIOM) members. PATIENTS AND METHODS A 30-item questionnaire was developed and delivered to all 1,832 AIOM members. RESULTS Six-hundred and eighty-five (37%) oncologists completed and returned the questionnaires. Sixty-three per cent felt culturally and psychologically prepared to face these issues. Fifty-four per cent believed that what had been decided while the patient enjoyed good health is no longer applicable in an advanced state of terminal illness. Thirty-nine per cent believed that doctors should abide by these directives, while 49% believed that this should be discussed on a case-by-case basis. Fourteen per cent of oncologists were favourable towards euthanasia and 42% only in particular circumstances. Fifty-six per cent had received at least one request for accelerating death: 15% consented, 50% discussed it with the patient and 31% refused. CONCLUSION Advance directives, euthanasia, accelerated death and life-sustaining treatment represent considerable challenges for Italian oncologists. Although prepared to face these issues, AIOM members ask for a debate within the medical world and for a shared judicial regulation.
Collapse
Affiliation(s)
- C Catania
- New Drugs Development Unit, Medical Oncology Division, European Institute of Oncology, Milan, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Munzone E, Nolé F, Zorzino L, Medici M, Minchella I, Cassatella MC, Casadio C, Picozzi M, Adamoli L, Goldhirsch A, Sandri M. Acquisition of HER2/neu over-expression on circulating tumor cells (CTCs) in patients (pts) with advanced breast cancer (ABC) during chemotherapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.11017] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Catania C, Micheli D, Minchella I, De Pas TM, Adamoli L, Medici M, Munzone E, Nolè F. Waiting room related symptoms: Patients’ experiences in an outpatient clinic of a cancer center. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.20614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Nolé F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, Medici M, Verri E, Adamoli L, Rotmensz N, Goldhirsch A, Sandri MT. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2007; 19:891-7. [PMID: 18056915 DOI: 10.1093/annonc/mdm558] [Citation(s) in RCA: 126] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND This study aimed to evaluate the prognostic significance of circulating tumor cells (CTCs) detection in advanced breast cancer patients. PATIENTS AND METHODS We tested 80 patients for CTC levels before starting a new treatment and after 4, 8 weeks, at the first clinical evaluation and every 2 months thereafter. CTCs were detected using the CellSearch System. RESULTS Forty-nine patients had >or=5 CTCs at baseline. At the multivariate analysis, baseline number of CTCs was significantly associated with progression-free survival [hazard ratio (HR) 2.5; 95% confidence interval (CI) 1.2-5.4]. The risk of progression for patients with CTCs >or=5 at last available blood draw was five times the risk of patients with 0-4 CTCs at the same time point (HR 5.3; 95% CI 2.8-10.4). Patients with rising or persistent >or=5 CTCs at last available blood draw showed a statistically significant higher risk of progression with respect to patients with <5 CTCs at both blood draws (HR 6.4; 95% CI 2.8-14.6). CONCLUSION CTCs basal value is a predictive indicator of prognosis and changes in CTC levels during therapy may indicate a clinical response. Testing CTC levels during targeted treatments might substitute other measurement parameters for response evaluation.
Collapse
Affiliation(s)
- F Nolé
- Division of Medical Oncology, Medical Care Unit, European Institute of Oncology, Milano, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Catania C, Medici M, Magni E, Munzone E, Cardinale D, Adamoli L, Sanna G, Minchella I, Radice D, Goldhirsch A, Nolè F. Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination. Ann Oncol 2007; 18:1969-75. [PMID: 17846020 DOI: 10.1093/annonc/mdm372] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Trastuzumab (T) combined with i.v. vinorelbine (i.v.VNR) is an active regimen for patients with advanced breast cancer (ABC). In order to further improve quality of life of patients undergoing treatment for ABC, a new regimen using oral vinorelbine (oVNR) (d1 + d3) plus q3wks T was tested (ToVNR). PATIENTS AND METHODS Thirty-nine patients with ABC, human epidermal growth factor receptor 2/neu 3+ or FISH positive received 288 treatment cycles with T 6 mg/kg (loading dose, 8 mg/kg) on d1 and oVNR 55 mg/m(2) on d1 + d3, q3wks until disease progression or unacceptable toxicity. RESULTS Thirty-seven patients and 286 treatment cycles were evaluated (two patients were lost to follow-up). Treatment was very well tolerated. Two patients had complete response (CR), 14 partial response (PR), 17 stable disease (SD) and four disease progression (PD) (overall response rate: 43%). Clinical benefit rate (CR + PR + SD >24 months) was 73%. Median time to progression was 8.9 months (range 2-27) and median duration of response was 10.9 months (range 2-27). CONCLUSIONS The ToVNR combination is active and very well tolerated. It favorably compares with the combination of T and weekly i.v. administered VNR, allowing a more convenient once every three weeks hospital admission and leaving patients and care providers free from the unpleasant effect of i.v.VNR.
Collapse
Affiliation(s)
- C Catania
- Division of Medical Oncology, Unit for Medical Care, Department of Medicine, European Institute of Oncology, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Sanna G, Franceschelli L, Rotmensz N, Botteri E, Adamoli L, Marenghi C, Munzone E, Cossu Rocca M, Verri E, Minchella I, Medici M, Catania C, Magni E, Goldhirsch A, Nolè F. Brain metastases in patients with advanced breast cancer. Anticancer Res 2007; 27:2865-9. [PMID: 17695462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
BACKGROUND The incidence of brain metastases (BM) is apparently rising in patients with advanced breast cancer (ABC). We performed a case control study to define current features of breast cancer related to central nervous system (CNS) metastases. PATIENTS AND METHODS From March 1999 to May 2006, we identified 72 patients with symptomatic BM of breast cancer. A comparison group was randomly selected assigning to each case two patients with primary breast cancer and no BM, matched for year of diagnosis, age and tumour stage (pT status and nodal status). RESULTS Cases had a significantly higher rate of negative estrogen receptors (ERs) (60% in cases vs. 29% in controls), negative progesterone receptors (PgRs) (79% vs. 43%), HER2/neu over expression (44% vs. 13%) and immunostaining for Ki-67 > or =20% (84% vs. 55%), with p-value <0.001 for all four parameters in univariate analyses. On multivariate analysis, HER2/neu over expression and Ki-67 -20% were independent predictive factors of brain relapse (Odds Ratio (OR) 2.55, 95% confidence intervals (CI) 1.10-5.94 and OR 2.97, 95% CI 1.01-8.73, respectively). Endocrine unresponsive tumours (both ER and PgR <10%) showed an increased risk of relapse with BM of borderline significance (OR 1.91, 95% CI 0.87-4.12). CONCLUSION Patients with ER and PgR negative tumours either with or without HER-2/neu over expression should be considered at higher risk of BM.
Collapse
Affiliation(s)
- G Sanna
- Department of Oncology, European Institute of Oncology, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Catania C, De Pas TM, Goldhirsch A, Radice D, Adamoli L, Medici M, Verri E, Marenghi C, de Braud F, Nolè F. Understanding the choice of participating in clinical trials. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.9091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9091 Background: The choice of whether to participate in a clinical trial by patients (pts) with cancer can be influenced, beyond trial information, by patient's own emotional and cultural properties, including past history as well as prejudices. Our hypothesis was that a better knowledge of these cultural and emotional features might be useful to improve patients-doctor dialogue, leading patients to a more conscious motivation to make the choice. Methods: We developed a 17-items, multiple-choice and open-answer questionnaire, to capture motivations for participating, or declining to take part, in clinical trials. Further information included family relationships, schooling and clinical symptoms. Patients were required to have advanced lung or breast cancer and to have never discussed participation in a clinical trial. Results: The questionnaire was answered by all the 42 pts who received it. Eighty-three percent of pts were positive about their participation. Trust in the investigator (43%) or in the Institute (21%) and hope to receive a new chance for cure (71%), both for themselves and for others, were a major motivation for a positive answer. Forty-eight percent thought participation in a clinical trial as a sign that no other “standard” treatments are available; 19% were worried of unknown side effects and 76% considered detailed information on expected toxicity to be helpful in making the decision. Sixty percent of patients were afraid of losing “precious time” by participating in a trial; 9% felt exploited as “guinea pigs” and 31% had a some degree of fear that a clinical trial is primarily motivated by economical interests. The most important reasons for accepting an oral experimental drug were its easy use (46%) and having more freedom (36%) Conclusions: Italian patients with advanced breast or lung cancer positively viewed participation in a clinical trial. Several hopes, prejudices and fears have been captured by the questionnaire, which might lead to improve the informed consent documentation and the consciousness of patients in taking their choice. Validation of the findings in a larger cohort of patients will lead to a study on the effect of a specific intervention on informing patients about clinical research. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Catania
- European Institute of Oncology, Milan, Italy
| | | | | | - D. Radice
- European Institute of Oncology, Milan, Italy
| | - L. Adamoli
- European Institute of Oncology, Milan, Italy
| | - M. Medici
- European Institute of Oncology, Milan, Italy
| | - E. Verri
- European Institute of Oncology, Milan, Italy
| | - C. Marenghi
- European Institute of Oncology, Milan, Italy
| | - F. de Braud
- European Institute of Oncology, Milan, Italy
| | - F. Nolè
- European Institute of Oncology, Milan, Italy
| |
Collapse
|
41
|
Catania C, Ascione G, Adamoli L, De Pas T, Medici M, Franceschelli L, Verri E, Magni E, Sanna G, Torrisi R, Goldhirsch A, Nolè F. Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre. Breast Cancer Res Treat 2007; 106:97-103. [PMID: 17260095 DOI: 10.1007/s10549-006-9481-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2006] [Accepted: 12/04/2006] [Indexed: 11/26/2022]
Abstract
PURPOSE Fulvestrant ('Faslodex') is an oestrogen receptor (ER) antagonist with no agonist effects. The drug was administered to heavily pre-treated patients with advanced breast cancer (ABC). Patients received Fulvestrant after disease progression (PD) on a previous endocrine treatment or as maintenance treatment after chemotherapy. MATERIAL AND METHODS Fifty-seven postmenopausal women with ER and/or progesterone receptor-positive ABC resistant to previous endocrine treatments prospectively received fulvestrant 250 mg via intramuscular injection q 28. RESULTS Twenty-seven patients received fulvestrant after PD and 30 received it as maintenance therapy after chemotherapy. All patients received fulvestrant as second-up to eight-line endocrine treatment for ABC. One patient (2%) had a partial response (PR) and 24 patients (42%) had stable disease > or =12 weeks (SD), including 11 patients who had SD > or =24 weeks. Thirty-two patients (56%) had de novo PD. Clinical benefit (CB; PR + SD > or =24 weeks) occurred in 12 patients (21%). Patients treated as maintenance and treated upon PD had 0 and 4% PR, 43 and 41% SD (including 20 and 19% SD > or =24 weeks), 57 and 55% PD, respectively. Overall, median time to progression (TTP) was 3 months. No differences in CB rate (20% vs. 23%), TTP (3 months vs. 3 months) and time to treatment failure (3 months vs. 3 months) were observed between patients receiving fulvestrant as maintenance therapy and those treated at PD on prior endocrine treatment. No grade 2-4 NCI-CTC toxicity was recorded. CONCLUSIONS Fulvestrant treatment was associated with prolonged CB and was well tolerated in this group of heavily pre-treated patients with ABC. The outcomes appeared to be similar for patients treated upon PD and those receiving fulvestrant as maintenance therapy.
Collapse
Affiliation(s)
- Chiara Catania
- Unit for Medical Care, Division of Medical Oncology, European Institute of Oncology, 20141, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Sanna G, Preda L, Bruschini R, Cossu Rocca M, Ferretti S, Adamoli L, Verri E, Franceschelli L, Goldhirsch A, Nolè F. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol 2006; 17:1512-6. [PMID: 16936182 DOI: 10.1093/annonc/mdl163] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND In recent years, several cases of mandibular necrosis associated with long-term use of bisphosphonates have been reported. The estimated incidence varies from 1% to 4.6%. PATIENTS AND METHODS We conducted an observational study with the aim of determining the incidence of jaw osteonecrosis in advanced breast cancer patients with bone metastases under bisphosphonate treatment and to identify subjects at higher risk of developing this complication evaluating preclinical signs. We considered two groups of patients. All the patients complaining of odontostomatological symptoms underwent maxillary CT scan and maxillo-surgeon clinical examination. Asymptomatic patients were asked to perform a standard orthopantomography (OPT). RESULTS From February 2005 to October 2005, we observed five patients with jaw bone necrosis (6%). Diagnosis was radiological and clinical. In two patients a confirmatory biopsy was performed. In the same time interval, OPTs were collected from 76 asymptomatic patients. Three OPTs revealed radiological features of suspicious mandibular necrosis. Maxillary CT scan confirmed the presence of an osteolityc area with signs of periosteal reaction. All the three patients were referred to maxillo-surgeon and two out of three patients underwent mandibular biopsy, but histopathological results were not conclusive. CONCLUSIONS In our experience, the incidence of jaw bone necrosis in breast cancer patients seems to be higher than in other reports (6%). Radiological features of suspicious jaw necrosis were observed in three asymptomatic patients. We do not know how these findings should be considered. Anyway, standard OPT is a simple procedure, and may allow identification of periodontal conditions that in some way can predispose to the development of this uncommon event.
Collapse
Affiliation(s)
- G Sanna
- Department of Medicine, Unit for Medical Care, European Institute of Oncology, Milan, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Nolè F, Verri E, Sanna G, Munzone E, Catania C, Ascione G, Adamoli L, Dellapasqua S, Colleoni M, Goldhirsch A. Pegylated liposomal doxorubicin (PLA) at a metronomic schedule for patients with advanced breast cancer (ABC). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.10571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10571 Background: The anti-angiogenic efficacy of chemotherapy (CT) is probably best obtained by administration of low doses of cytotoxics on a frequent or continuous schedule. The aim of this pilot study was to assess feasibility, clinical efficacy and tolerability of PLA, using a “metronomic” schedule in ABC. This schedule has been previously tested in the treatment of Kaposi sarcoma. Methods: From January to November 2005, 36 pts with ABC were treated with PLA, at a dose 20 mg/m2 q14. Almost all the pts were heavily pretreated for ABC and 44% of them received previous anthracycline therapy in adjuvant or metastatic setting. Results: Thirty-four pts were evaluable for toxicity and 29 for response. One pt (3%) had CR, 3 (11%) PR, 12 (41%) NC and 13 (45%) PD, for an overall clinical benefit of 28%. Median response duration was 2.59 mos; median TTP was 3.38 mos (95% CI 2.11–4.64). Treatment was well tolerated with neither G3-G4 NCI-CTC hematological toxicity. Only one pt experienced G3 palmar-plantar erythrodysesthesia (PPE). PPE was observed in other 15 pts (39%), with G2 occurring in 7 (21%). Other common G2 non-hematological toxicities were mucositis in 3 pts (9%) and constipation in 3 pts (9%) Dose reduction, due to subjective or hematological toxicity, was required in 10 pts (36%). No decrease in LVEF > 10% from baseline was observed. Conclusions: Metronomic PLA schedule in pretreated ABC pts seems to be an active and well-tolerated regimen. As to dose-dense CT, targets of metronomic CT might be, in addition to malignant cells, also endothelial and other stromal cells of the progressing metastasis, leading ultimately to the stability and eventually regression of the neoplastic lesion. The lower toxicity profile of the metronomic schedules make their use in pts with ABC very attractive and their testing in the adjuvant setting extremely challenging. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- F. Nolè
- European Institute of Oncology, Milan, Italy
| | - E. Verri
- European Institute of Oncology, Milan, Italy
| | - G. Sanna
- European Institute of Oncology, Milan, Italy
| | - E. Munzone
- European Institute of Oncology, Milan, Italy
| | - C. Catania
- European Institute of Oncology, Milan, Italy
| | - G. Ascione
- European Institute of Oncology, Milan, Italy
| | - L. Adamoli
- European Institute of Oncology, Milan, Italy
| | | | - M. Colleoni
- European Institute of Oncology, Milan, Italy
| | | |
Collapse
|
44
|
Nolè F, Catania C, Sanna G, Imadalou K, Munzone E, Adamoli L, Longerey B, Blanchot G, Goldhirsch A. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 2006; 17:322-9. [PMID: 16303864 DOI: 10.1093/annonc/mdj058] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
PURPOSE A phase I study was performed to determine the maximal tolerated dose, recommended doses (RDs), safety and efficacy of oral vinorelbine when combined with capecitabine in an all-oral chemotherapy regimen in patients with metastatic breast cancer (MBC), with pharmacokinetic blood sampling to investigate potential drug-drug interactions. PATIENTS AND METHODS Forty-four patients with MBC received as first- or second-line chemotherapy, oral vinorelbine at a dose of 60 or 80 mg/m2 on days 1 and 8 (and 15) with escalating doses of capecitabine from 1650 to 2500 mg/m2/day days 1-14 every 3 or 4 weeks. Three schedules were tested: day 1, day 8 and weekly regimens of oral vinorelbine with a 14-day course of capecitabine every 3 weeks; and a days 1 and 8 regimen of oral vinorelbine with a 14-day course of capecitabine every 4 weeks. RESULTS With oral vinorelbine at 60 mg/m2, the RDs were established as oral vinorelbine 60 mg/m2 on days 1 and 8 plus capecitabine 2250 mg/m2/day days 1-14 and oral vinorelbine 60 mg/m2/week plus capecitabine 2000 mg/m2/day days 1-14. With oral vinorelbine at 80 mg/m2, the RD was oral vinorelbine 80 mg/m2 on days 1 and 8 plus capecitabine 2000 mg/m2/day days 1-14. Neutropenia was the main dose-limiting toxicity of the combination; it was reported in 40 patients (90.9%), with grade 3 in 14 patients (31.8%) and 6.2% of cycles, and grade 4 in 12 patients (27.3%) and 4.3% of cycles. Complications were rare with only three patients experiencing febrile neutropenia (one episode each). The most frequent non-haematological toxicity was gastrointestinal; however, the incidence of grade 3 was low, with no episode of grade 4. Hand-foot syndrome was reported in 14 patients (31.8%) and 22.6% of cycles, with grade 2 in two patients (4.5%) and 1.2% of cycles (two episodes each). No episode of grade 3 was observed. Objective responses were reported in 18 patients (three complete responses and 15 partial responses), yielding a response rate of 40.9% in the intention-to-treat population according to the investigator assessment. Results from the pharmacokinetic study demonstrated the absence of mutual pharmacokinetic interactions when both drugs were co-administered. CONCLUSIONS The combination of oral vinorelbine and capecitabine is safe and easy to administer in an outpatient setting. This all-oral combination chemotherapy may offer a good alternative to the intravenous route for patients with MBC. Based on these promising results, a phase II study has started using oral vinorelbine 60 mg/m2/week with capecitabine 2000 mg/m2/day days 1-14 every 3 weeks as first-line chemotherapy in patients with MBC.
Collapse
Affiliation(s)
- F Nolè
- European Institute of Oncology, Milan, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Nolè F, Catania C, Munzone E, Rocca A, Verri E, Sanna G, Ascione G, Adamoli L, Zampino MG, Minchella I, Goldhirsch A. Capecitabine/Vinorelbine: An Effective and Well-Tolerated Regimen for Women with Pretreated Advanced-Stage Breast Cancer. Clin Breast Cancer 2006; 6:518-24. [PMID: 16595035 DOI: 10.3816/cbc.2006.n.005] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
BACKGROUND The combination of capecitabine and vinorelbine is a potentially valuable treatment regimen for patients with advanced-stage breast cancer. The drugs are easy to administer and do not cause significant alopecia. In order to identify the spectrum of toxicity of a regimen containing 2 drugs, we conducted an extended phase I study aimed at defining maximum tolerated doses, recommended doses, safety, and efficacy in patients with pretreated advanced-stage breast cancer. PATIENTS AND METHODS Forty-nine patients with advanced-stage breast cancer were treated with escalating doses of oral capecitabine from 500 mg/m2 to 1375 mg/m2 twice daily on days 1-14 and escalating doses of vinorelbine from 12.5 mg/m2 to 25 mg/m2 intravenously (I.V.) on days 1 and 3 every 3 weeks. Almost all patients (90%) had received >or= 3 previous treatments for metastatic disease (anthracyclines, 76%; 5-flourouracil, 76%; taxanes, 29%). RESULTS Dose level 9 (capecitabine 1250 mg/m2 twice daily on days 1-14 and vinorelbine 22.5 mg/m2 I.V. on days 1 and 3) was identified as the maximum tolerated dose. The most frequent clinical adverse events were nausea (78%), asthenia (59%), constipation (51%), mucositis (47%), and hand-foot syndrome (41%). The majority of events were mild to moderate; the only grade 4 clinical adverse events were diarrhea, fever, and thromboembolism, each of which occurred in 1 patient (2%) at dose level 8. Objective confirmed responses were observed in 18 patients (37%), including 1 complete response (2%) and 17 partial responses (35%). Disease was stable in an additional 10 patients (20%), with a median duration of 6.3 months (range, 4-24 months). CONCLUSION The combination of the 2 drugs is very well tolerated and effective, especially considering the previous exposure to chemotherapy. The recommended dose for further phase II studies should be capecitabine 1250 mg/m2 twice daily on days 1-14 and vinorelbine 22.5 mg/m2 I.V. on days 1 and 3.
Collapse
Affiliation(s)
- Franco Nolè
- Department of Medicine, European Institute of Oncology, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Nolè F, Catania C, Sanna G, Adamoli L, Imadalou K, Zorza G, Bodini A, Goldhirsch A. Dose finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine in metastatic breast cancer (MBC) patients: Final results. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.666] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. Nolè
- European Institute of Oncology, Milan, Italy; Inst de Recherche Pierre Fabre, Boulogne, France; Inst de Recherche Pierre Fabre, Castres, France; Pierre fabre Pharma, Milan, Italy
| | - C. Catania
- European Institute of Oncology, Milan, Italy; Inst de Recherche Pierre Fabre, Boulogne, France; Inst de Recherche Pierre Fabre, Castres, France; Pierre fabre Pharma, Milan, Italy
| | - G. Sanna
- European Institute of Oncology, Milan, Italy; Inst de Recherche Pierre Fabre, Boulogne, France; Inst de Recherche Pierre Fabre, Castres, France; Pierre fabre Pharma, Milan, Italy
| | - L. Adamoli
- European Institute of Oncology, Milan, Italy; Inst de Recherche Pierre Fabre, Boulogne, France; Inst de Recherche Pierre Fabre, Castres, France; Pierre fabre Pharma, Milan, Italy
| | - K. Imadalou
- European Institute of Oncology, Milan, Italy; Inst de Recherche Pierre Fabre, Boulogne, France; Inst de Recherche Pierre Fabre, Castres, France; Pierre fabre Pharma, Milan, Italy
| | - G. Zorza
- European Institute of Oncology, Milan, Italy; Inst de Recherche Pierre Fabre, Boulogne, France; Inst de Recherche Pierre Fabre, Castres, France; Pierre fabre Pharma, Milan, Italy
| | - A. Bodini
- European Institute of Oncology, Milan, Italy; Inst de Recherche Pierre Fabre, Boulogne, France; Inst de Recherche Pierre Fabre, Castres, France; Pierre fabre Pharma, Milan, Italy
| | - A. Goldhirsch
- European Institute of Oncology, Milan, Italy; Inst de Recherche Pierre Fabre, Boulogne, France; Inst de Recherche Pierre Fabre, Castres, France; Pierre fabre Pharma, Milan, Italy
| |
Collapse
|
47
|
Maggiolini A, Grassi R, Adamoli L, Corbetta A, Charmet GP, Provantini K, Fraschini D, Jankovic M, Lia R, Spinetta J, Masera G. Self-image of adolescent survivors of long-term childhood leukemia. J Pediatr Hematol Oncol 2000; 22:417-21. [PMID: 11037852 DOI: 10.1097/00043426-200009000-00006] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The purpose of our research was to evaluate the attitude to face the life cycle and the impact that the experience of childhood leukemia may have had in a group of adolescents who had the disease cured. A questionnaire was administered at the Pediatric Hematology Center, San Gerardo Hospital, Monza, Italy, to all former patients age 12 to 20 years and off therapy from leukemia for at least 2 years (total of 116 adolescents) during 1997; 70 patients responded to the mailing and a comparison group of 70 secondary-school students was investigated. The two groups were matched as closely as possible on key characteristics (age, gender, socio-economic level of families, education and occupation of the parents, and geographic area of residence). The Offer Self-Image Questionnaire was the instrument used in this study. Overall, the teenagers in whom leukemia was cured showed a more positive and mature self-image (psychologic, social, attitude toward family, and coping) compared with the student group (statistical evidence, P < 0.05). An effective psychosocial support for patients and their families during their treatment, in addition to medical therapy, is strongly recommended. The majority of survivors of childhood cancer grow successfully without serious psychologic sequelae.
Collapse
Affiliation(s)
- A Maggiolini
- Faculty of Psychology, 2nd University of Milan, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Masera G, Jankovic M, Adamoli L, Corbetta A, Fraschini D, Lia R, Collino L, Locati A, Pertici S, Bissi R, Bertolini M, Verga G, Spinetta JJ. The psychosocial program for childhood leukemia in Monza, Italy. Ann N Y Acad Sci 1997; 824:210-20. [PMID: 9382446 DOI: 10.1111/j.1749-6632.1997.tb46224.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- G Masera
- Clinica Pediatrica, Università di Milano, Ospedale San Gerardo, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Adamoli L, Deasy-Spinetta P, Corbetta A, Jankovic M, Lia R, Locati A, Fraschini D, Masera G, Spinetta JJ. School functioning for the child with leukemia in continuous first remission: screening high-risk children. Pediatr Hematol Oncol 1997; 14:121-31. [PMID: 9089740 DOI: 10.3109/08880019709030898] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
It is well known in the literature that cancer creates educationally related barriers for all children, which may or may not contribute to clinically relevant school problems. The goal of this study was to obtain a base rate for the characteristic pattern of school functioning for children with leukemia, so that the children with the most serious difficulties might be discovered and given the different and flexible help needed. From 1988 through 1994, a questionnaire was administered annually to teachers of all leukemic children in our center. The 291 questionnaire were used to compare the school functioning of children with leukemia with that of matched controls chosen by each teacher as representative of the class as a whole, excluding special education and developmentally disabled students. This approach to matching was chosen as a control for socioeconomic factors as well. The study was conducted with all patients with leukemia entering the center residing in the region of Lombardy, attending school, and either in therapy or out of therapy. After initial treatment, the children with leukemia in our center as a group attended school regularly and willingly. Analyses of variance (ANOVAs) were conducted on the total scores and on scores for each of the subareas of learning, socialization, and emotionality. T-tests, were given to contrast individual item scores of patients with those of their matched controls. On most individual items, children with leukemia did not differ from their classmates. However, significant discrepancies between children with leukemia and their classmates appeared consistently year after year on overall total scores and on each of the three major subcomponents of the test (learning, socialization, and emotionality). The groups most affected were children who were cranially irradiated and children who were under 6 years of age at diagnosis. Children who have been irradiated and children diagnosed under 6 years of age have the greatest risk for difficulties in school functioning and are candidates for greater attention and preventive efforts.
Collapse
Affiliation(s)
- L Adamoli
- Department of Pediatrics, Hospital S. Gerardo, Monza, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Naldi L, Adamoli L, Fraschini D, Corbetta A, Imberti L, Reseghetti A, Reciputo A, Rossi E, Cainelli T, Masera G. Number and distribution of melanocytic nevi in individuals with a history of childhood leukemia. Cancer 1996; 77:1402-8. [PMID: 8608522 DOI: 10.1002/(sici)1097-0142(19960401)77:7<1402::aid-cncr27>3.0.co;2-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
BACKGROUND An increased number of melanocytic nevi at the termination of chemotherapy has been documented in children with hematologic malignancies. The persistence of the increased number of nevi over time and the relationship with personal (e.g. phenotype) and disease related variables remain to be explored. METHODS One hundred Italian patients diagnosed as having acute lymphatic or myeloid leukemia, after 1975, were recruited and compared with a group of 100 control individuals drawn from friend of the enrolled patients. Information regarding lifetime sun exposure, phenotypic characteristics, and number of nevi was collected by experienced dermatologists. Counts of nevi were expressed both as totals and as counts per unit of body surface area ("density"). Multiple linear regression analysis was employed to control for potentially confounding factors when comparing patients and controls. RESULTS The patients and controls were fairly comparable in terms of constitutional characteristics, but the patients had a significantly higher number and density of nevi > or = 2 mm or larger in diameter. In addition, patients had a greater number of large nevi ( > or = 6 mm in greatest dimension), and of nevi in unusual areas, such as the palms and soles. Differences in nevus density between patients and controls were notably maintained in the older age group ( > 12 years). None of the disease-related factors analyzed (e.g. treatment protocol and radiotherapy), appeared to be significantly correlated with nevus density. CONCLUSIONS Patients with a history of childhood leukemia have a sustained increase in their nevus density. A fairly convincing body of evidence indicates that a large number of melanocytic nevi is the strongest risk factor for melanoma. Therefore, the utility of periodic skin examination of these should be considered.
Collapse
Affiliation(s)
- L Naldi
- Department of Dermatology, University of Milan, Bergamo General Hospital, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|